S
Seung-Mo Hong
Researcher at University of Ulsan
Publications - 383
Citations - 21628
Seung-Mo Hong is an academic researcher from University of Ulsan. The author has contributed to research in topics: Pancreatic cancer & Cancer. The author has an hindex of 53, co-authored 361 publications receiving 17907 citations. Previous affiliations of Seung-Mo Hong include University of Virginia Health System & Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
Notch3 signaling is associated with MUC5AC expression and favorable prognosis in patients with small intestinal adenocarcinomas.
TL;DR: Notch3 signaling, associated with MUC5AC expression, could be a more favorable prognostic factor in SIACs, and findings indicate that Notch3 signaled as a tumor promoter or suppressor depending on the cellular context and cross-talk with other signaling pathways.
Journal ArticleDOI
Luschka Ducts of the Gallbladder in Adults: Case Series Report and Review of the Medical Literature.
TL;DR: Luschka ducts of the gallbladder may harbor varied aspects, from duct-like or cystic, to nodular, biliary adenoma-like complexes, as well as for immunohistochemical features.
Journal ArticleDOI
Comparative meta-analysis between human and mouse cancer microarray data reveals critical pathways
TL;DR: This work has analysed data from 87 microarray datasets, spanning 25 different types of cancer, and identified several hundred pathways that are statistically significant (p < 0.01) and deregulated in cancer.
Journal ArticleDOI
Prognostic implications of immune classification in a multicentre cohort of patients with small intestinal adenocarcinoma.
TL;DR: Categorising primary SIAC into four types of tumour immune microenvironments and proposing a strategy for identifying patient subgroups that are most likely to be immunotherapy-responsive can be useful in predicting the prognosis of patients and the identification of immun therapy-responsive subgroups.
Journal ArticleDOI
Clinicopathological significance of olfactomedin-4 in extrahepatic bile duct carcinoma.
TL;DR: High OLFM4 expression predicted less aggressive clinical behavior in patients with EBDC and might play an important role in carcinogenesis and in the progression from BilINs to EBDCs.